Jacobs Levy Equity Management, Inc Macrogenics Inc Transaction History
Jacobs Levy Equity Management, Inc
- $24.2 Billion
- Q2 2025
A detailed history of Jacobs Levy Equity Management, Inc transactions in Macrogenics Inc stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 1,004,798 shares of MGNX stock, worth $1.53 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
1,004,798
Previous 665,351
51.02%
Holding current value
$1.53 Million
Previous $844,000
43.96%
% of portfolio
0.01%
Previous 0.0%
Shares
26 transactions
Others Institutions Holding MGNX
# of Institutions
118Shares Held
52.3MCall Options Held
55.3KPut Options Held
35.9K-
Bellevue Group Ag Kuesnacht, V89.92MShares$15.1 Million0.27% of portfolio
-
Armistice Capital, LLC New York, NY5.96MShares$9.06 Million0.13% of portfolio
-
Black Rock Inc. New York, NY5.4MShares$8.21 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.21MShares$6.4 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT3.25MShares$4.94 Million0.02% of portfolio
About MACROGENICS INC
- Ticker MGNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 61,458,800
- Market Cap $93.4M
- Description
- MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...